INTRODUCTION AND OBJECTIVES: Pathologic complete response after neoadjuvant chemotherapy (NAC) is associated with better overall (OS) and recurrence free survival (RFS). Whereas, delay in cystectomy has been reported to be associated with worse outcomes. We sought to better understand the consequences of administering NAC to those who did not benefit from it by comparing oncological outcomes to patients who were eligible for NAC but underwent immediate cystectomy.
INTRODUCTION AND OBJECTIVES: Robot-assisted laparoscopic radical cystectomy (RARC) has evolved as a reproducible minimally invasive alternative to open radical cystectomy (ORC) with non-inferior oncologic outcomes. Concerns have been raised that offering RARC was associated with deprivation of patients from continent urinary diversion (CUD). We aimed to evaluate contemporary practice patterns in radical cystectomy and urinary diversion.
METHODS: We investigated the National Cancer Database (NCDB) for patients with localized MIBC clinical stage cT2-T4M0 who underwent radical cystectomy (RC). Utilization trends of ORC, RARC, CUD and ileal conduit urinary diversion (ICUD) were analyzed. Multivariable logistic regression models were fitted to asses factors associated with adoption of RARC and CUD.
RESULTS: A total of 14,466 RCs were performed from 2010 to 2015. Of these, 9,356 (64.68%) were ORC and 4,914 (33.97%) were RARC.
There was a significant increase in adoption of RARC from (10.72%) in 2010 to (20.86%) in 2015 (r2[0.9660, p<0 .001) (Figure 1) .
Across all years ICUD was the primary mode of urinary diversion, CUD was only offered in 2.70 % in 2010 compared to 2.06 % in 2015 (r2[0.330, p[0.223). Among patients who underwent RARC only 2.44% received CUD, a similar proportion was noted in ORC group 2.66%.
Multivariate analysis identified male gender, age lower than 60, surgery at academic center, and T2 stage as independent predictors of receiving CUD. Similarly, later year of diagnosis, male gender and T2 stage, were independent predictors of receipt of RARC.
Conversion from RARC to ORC occurred in 3.8% of cases, later year of diagnosis was associated with decreased risk of open conversion (2015 vs 2010 OR : 0.31, 95% CI 0.19-0.52 p<0.001).
CONCLUSIONS: There is a significant nationwide increasing trend of adoption of MIRC. This diffusion was not associated with decline in CUD which remains significantly underutilized in both open and minimally invasive groups.
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INTRODUCTION AND OBJECTIVES: In the last 15 years robotic surgery became the leading approach for treatment of prostate and kidney cancer. Following the success of these procedures, robotic system has been more recently applied to treat bladder cancer (BCa) but sparse data exists regarding the diffusion of robotic radical cystectomy (RARC) and its trend in contemporary patients. Aim of our study is comparing utilization trends and time-changes in perioperative outcomes of RARC using data from a large multicenter collaboration.
METHODS: We retrospectively evaluated data from 2,713 patients treated with open radical cystectomy (ORC) and RARC for BCa at 16 American and European institutions between 2006 and 2018. All patients had completed data regarding pre-, intra-e post-operative characteristics. The Kruskal-Wallis test and Chi-square test evaluated differences between continuous and categorical variables, respectively.
